The UK is increasing production capacity for the COVID-19 vaccine.

The UK government has signed an 18-month deal with biotech group Wockhardt to boost production of the COVID-19 vaccine.
Production of the COVID-19 vaccine is expected to begin in September 2020, according to a statement released yesterday by the British government. production of the
will take place at CP Pharmaceuticals, a Wockhardt subsidiary in Wockhardt, Westham, North Wales.
CP Pharmaceuticals has the ability to produce millions of doses of coronavirus vaccine. Alok Sharma,
's business secretary, said: "The UK has the ability to research, develop and produce safe and effective vaccines, which are vital to the fight against the coronavirus.
Today, we have acquired additional capabilities to produce millions of doses of THE COVID-19 candidate vaccine to guarantee the vaccine availability."
deal with Wockhardt, the new vaccine manufacturing and innovation centre will continue to be built in Oxfordshire, England. Kate Bingham, chairman of the
UK Vaccines Working Group, said: "The agreement with Wockhardt will increase our production capacity to ensure the required number of vaccines is produced."
in July, the Oxford University vaccine trial had an immune response in all of the people tested without worrying side effects.
the Oxford Team found that 14 days after the injection, T-cells peaked in the volunteers and antibodies peaked 28 days after injection.
the results were published July 20 in the Lancet, the world's top medical journal, but the study is limited in length and it is unclear how long these T-cells and antibodies will last in the body.
.